Search
Mafenide
go.drugbank.com/drugs/DB06795ApprovedVet approvedWithdrawnIn November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements
Entrectinib
go.drugbank.com/drugs/DB11986ApprovedInvestigational[L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors.
Licofelone
go.drugbank.com/drugs/DB04725ExperimentalIt is currently under evaluation as a treatment for osteoarthritis (OA), the most common form of arthritis. … Although phase III trials have been successfully completed in OA patients no dates for regulatory submission have yet been given.
Rosin
go.drugbank.com/drugs/DB11165ApprovedRosin is a solid form of resin obtained from pines and other plants, mostly conifers. It is prepared from heating fresh liquid resin to vaporize the volatile liquid terpene components.
Categories: Compounds used in a research, industrial, or household settingAtractylodes japonica root oil
go.drugbank.com/drugs/DB11270ApprovedWithdrawnIt is present in some cosmetic products such as whitening creams as an active ingredient and lubricant for skin irritation.
Acadesine
go.drugbank.com/drugs/DB04944InvestigationalAcadesine has been granted Orphan Drug Designation for B-CLL in the EU. … Acadesine (AICA-riboside) is a purine nucleoside analog with anti-ischemic properties that is currently being studied (Phase 3) for the prevention of adverse cardiovascular outcomes in patients undergoing
Piperaquine
go.drugbank.com/drugs/DB13941ApprovedInvestigationalEurartesim was first authorized for market by the European Medicines Agency in October 2011.
Lunsotogene parvec
go.drugbank.com/drugs/DB18278ApprovedInvestigationalLunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss. … [L56136] On April 23, 2026, the FDA granted accelerated approval for the treatment of pediatric and adult patients with severe-to-profound hearing loss associated with molecularly confirmed biallelic
Udifitimod
go.drugbank.com/drugs/DB19053InvestigationalUdifitimod is under investigation in clinical trial NCT05014438 (A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis).